Compounds > ly 300164
Page last updated: 2024-09-05

ly 300164 and 2,3-dihydroxyquinoxaline

ly 300164 has been researched along with 2,3-dihydroxyquinoxaline in 1 studies

Compound Research Comparison

Studies
(ly 300164)		Trials
(ly 300164)		Recent Studies (post-2010)
(ly 300164)		Studies
(2,3-dihydroxyquinoxaline)		Trials
(2,3-dihydroxyquinoxaline)		Recent Studies (post-2010) (2,3-dihydroxyquinoxaline)
737122509

Protein Interaction Comparison

ProteinTaxonomyly 300164 (IC50)2,3-dihydroxyquinoxaline (IC50)
Glutamate receptor ionotropic, NMDA 2DHomo sapiens (human)9.8
Glutamate receptor ionotropic, NMDA 3BHomo sapiens (human)9.8
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)9.8
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)9.8
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)9.8
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)9.8
Glutamate receptor ionotropic, NMDA 1Homo sapiens (human)9.8
Glutamate receptor ionotropic, NMDA 2AHomo sapiens (human)9.8
Glutamate receptor ionotropic, NMDA 2BHomo sapiens (human)9.8
Glutamate receptor ionotropic, NMDA 2CHomo sapiens (human)9.8
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)9.8
Glutamate receptor ionotropic, NMDA 3AHomo sapiens (human)9.8
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)9.8
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)9.8

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Carcache, D; Kalkman, HO; Koller, M; Mattes, H1

Other Studies

1 other study(ies) available for ly 300164 and 2,3-dihydroxyquinoxaline

ArticleYear
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside.
    Journal of medicinal chemistry, 2010, Aug-12, Volume: 53, Issue:15

    Topics: Analgesics; Animals; Anticonvulsants; Antipsychotic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Neuroprotective Agents; Protein Subunits; Receptors, AMPA

2010